With the FDA's first peptide compounding panel now days away — the Pharmacy Compounding Advisory Committee (PCAC) meets July 23-24, 2026 on seven peptides — attention is already turning to what comes next. The FDA has confirmed a second PCAC session before the end of February 2027, and the agenda names five more compounds: GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF (pegylated mechano growth factor).
That second list matters more to our readers than the first. GHK-Cu and Melanotan II are two of the most-searched, most-bought peptides on the market — and unlike the July lineup, they anchor whole categories of buyer interest: skin and hair, tanning and libido, cognition, tissue repair. Here is exactly what the second round is, what it does and doesn't change, and where each of these stands for buyers right now.
Research-context information only. GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF are sold for research purposes only. The regulatory details below come from public FDA records and reporting. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What the FDA actually scheduled
When the FDA removed a batch of peptides from its Category 2 "may not be compounded" list in April 2026, it split the follow-up review into two PCAC sessions rather than one marathon meeting. The first session (July 23-24, 2026) takes up seven peptides: BPC-157, TB-500, KPV, MOTS-c on day one, and DSIP (emideltide), Semax, and Epitalon on day two. We break that meeting down in our 7 peptides going to FDA vote guide.
The second session, which the FDA has said will convene before the end of February 2027, covers five substances nominated for the 503A Bulk Drug Substances List — the list that lets a compounding pharmacy prepare a substance against an individual prescription:
| Compound | Common use category | Status for buyers |
|---|---|---|
| GHK-Cu | Skin, hair, wound repair | Widely sold research-use-only |
| Melanotan II | Tanning, libido | Widely sold research-use-only |
| LL-37 (cathelicidin) | Antimicrobial, immune | Widely sold research-use-only |
| Dihexa | Cognition, synaptogenesis | Widely sold research-use-only |
| PEG-MGF | Muscle repair signaling | Niche research-use-only |
A few details worth getting right. The exact date, location, and public-comment docket for the February 2027 session have not been set yet — the FDA said it will publish a Federal Register notice with those specifics and an opportunity to request open-hearing presentation slots. And the committee is advisory: PCAC recommends, the FDA rules later, and any formal rulemaking to add a substance to the 503A list would run well into 2027 or beyond even after a favorable vote.
What this means for you
The single most important point: the February 2027 review changes nothing about access or pricing today. These five compounds are sourced the same way next month as they were last month. A PCAC session is an upside vote — it asks whether a new legal compounding channel should open, not whether the existing research-use-only market should close. Even a clean sweep of favorable recommendations would only create a prescription-gated pharmacy route, months to years out, on top of what already exists.
So if the headlines have readers checking on GHK-Cu or Melanotan II, the practical picture is unchanged — and here is where the four buyable compounds in this round stand:
- Best GHK-Cu Vendors — the copper peptide most commonly used in collagen, skin, and hair protocols. Live cost-per-mg and COA status across recommended vendors.
- Best Melanotan II Vendors — current pricing on the tanning peptide, one of the highest-demand searches in the category.
- Best Dihexa Vendors — the angiotensin-IV-derived cognition compound, already off the Category 2 list.
- Best LL-37 Vendors — the antimicrobial cathelicidin peptide.
- All Active Vendor Coupons — current discount codes across recommended vendors.
PEG-MGF is the outlier of the five — a niche muscle-signaling compound with a much thinner vendor and research footprint than the other four, so it draws far less buyer interest.
